Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

652
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
Cancer Vaccines01:30

Cancer Vaccines

503
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
503
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.2K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.2K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

1.7K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

KSHV-infected endothelial cells expand and up-regulate angiogenic pathways and CXCR4 in patient-derived Kaposi sarcoma models.

Science translational medicine·2026
Same author

Early antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trial.

BMC cancer·2026
Same author

Driving in the right direction: new insights into genomic drivers of HIV-associated diffuse large B-cell lymphoma.

AIDS (London, England)·2026
Same author

Kaposi sarcoma herpesvirus (KSHV) subtypes and impact on outcomes in KSHV-associated diseases.

The Journal of infectious diseases·2026
Same author

Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study.

Blood·2026
Same author

Tocilizumab as stabilizing frontline treatment in suspected KSHV inflammatory cytokine syndrome.

Blood advances·2026
Same journal

Combination adjuvants: clinical value and mechanisms of action.

Current opinion in virology·2026
Same journal

Editorial Overview: Immunopathogenesis in viral disease.

Current opinion in virology·2026
Same journal

Architecture and evolution of viral complement evasion.

Current opinion in virology·2026
Same journal

The HEV capsid through a dynamic lens: parallels and divergence from caliciviruses.

Current opinion in virology·2026
Same journal

When structural rationales fall short: revisiting the immunogenicity of herpesvirus prefusion and postfusion glycoprotein B.

Current opinion in virology·2026
Same journal

Beyond brain fog: viral proteins as convergent drivers of neuroinflammation and proteinopathy.

Current opinion in virology·2026
See all related articles

Related Experiment Video

Updated: Sep 5, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.0K

Immunotherapy for KSHV-associated diseases.

Kathryn Lurain1, Robert Yarchoan1, Ramya Ramaswami1

  • 1HIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Current Opinion in Virology
|July 8, 2022
PubMed
Summary
This summary is machine-generated.

Immunotherapies show promise for Kaposi sarcoma herpesvirus (KSHV)-associated diseases, which thrive in immune-compromised individuals. Research explores agents like monoclonal antibodies to restore KSHV-specific immunity.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K
Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV
07:02

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV

Published on: September 14, 2010

12.7K

Related Experiment Videos

Last Updated: Sep 5, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.0K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K
Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV
07:02

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV

Published on: September 14, 2010

12.7K

Area of Science:

  • Immunology
  • Virology
  • Oncology

Background:

  • Kaposi sarcoma herpesvirus (KSHV)-associated diseases, including Kaposi sarcoma and multicentric Castleman disease, are linked to immune suppression and loss of KSHV-specific immunity.
  • These conditions disproportionately affect individuals with HIV or primary/iatrogenic immune deficiencies.
  • KSHV actively modulates the host immune system through viral cytokine homologs and immune evasion strategies.

Purpose of the Study:

  • To review the current role and potential of various immunotherapies in managing KSHV-associated diseases.
  • To highlight KSHV-associated diseases as critical targets for immunotherapeutic intervention due to their association with immune dysregulation.

Main Methods:

  • Review of existing literature on immunotherapies investigated for KSHV-associated diseases.
  • Analysis of viral mechanisms employed by KSHV to evade immune surveillance.
  • Identification of therapeutic agents currently under investigation or in clinical use.

Main Results:

  • Several immunotherapeutic agents, including monoclonal antibodies, immunomodulatory drugs, and therapeutic cytokines, have been studied for KSHV-associated diseases.
  • KSHV's immune-modulating properties present unique challenges and opportunities for immunotherapy development.
  • The efficacy and safety profiles of these agents are under ongoing investigation.

Conclusions:

  • Immunotherapy represents a promising strategy for treating KSHV-associated diseases, particularly in immunocompromised populations.
  • Further research and clinical trials are essential to optimize immunotherapy approaches for these conditions.
  • Understanding KSHV's interaction with the immune system is crucial for developing effective treatments.